OncoTherapy Science(JP:4564)
Â¥16.00-1.00 (-5.88%)
JP:4564
OncoTherapy Science financials statements
Â¥16.00
At close:-1.00 (-5.88%)
Want to see JP:4564 full AI Analyst Report?
OncoTherapy Science (4564) Ratios
2 Followers
OncoTherapy Science Ratios
JP:4564's free cash flow for Q4 2024 was ¥0.00. For the 2024 fiscal year, JP:4564's free cash flow was increased by ¥0.00 and operating cash flow was ¥0.00. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 25 | Mar 24 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 13.59 | 3.37 | 2.27 | 2.33 | 16.39 |
| Quick Ratio | 13.22 | 3.13 | 2.07 | 2.17 | 16.18 |
| Cash Ratio | 12.29 | 2.54 | 1.47 | 1.83 | 14.87 |
| Solvency Ratio | -4.19 | -0.04 | -2.51 | -1.68 | -5.19 |
| Operating Cash Flow Ratio | -5.43 | -2.49 | -3.41 | -1.30 | -9.04 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | ¥ 2.09B | ¥ 679.61M | ¥ 304.16M | ¥ 765.99M | ¥ 2.90B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.04 | 0.12 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.07 | 0.30 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.07 | 0.23 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.07 | 0.23 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.10 | 1.58 | 2.45 | 1.77 | 1.09 |
| Debt Service Coverage Ratio | -619.79 | -677.84 | -5907.88 | 0.00 | 0.00 |
| Interest Coverage Ratio | -618.14 | -664.39 | -5141.28 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.01 | 0.03 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.20 | 0.50 | 0.00 | 0.00 |
| Net Debt to EBITDA | 2.58 | 0.96 | 0.33 | 1.02 | 1.82 |
| Profitability Margins | |||||
| Gross Profit Margin | 1.73% | -1.70% | -29.13% | 3.67% | 5.88% |
| EBIT Margin | -100.23% | -108.25% | -210.70% | -98.37% | -492.65% |
| EBITDA Margin | -100.23% | -108.25% | -210.70% | -96.13% | -477.93% |
| Operating Profit Margin | -100.23% | -106.38% | -183.70% | -97.49% | -492.65% |
| Pretax Profit Margin | -112.36% | -108.41% | -210.73% | -98.37% | -469.21% |
| Net Profit Margin | -112.63% | -108.70% | -211.13% | -98.57% | -469.70% |
| Continuous Operations Profit Margin | -112.63% | -108.70% | -211.13% | -98.57% | -469.70% |
| Net Income Per EBT | 100.24% | 100.27% | 100.19% | 100.20% | 100.10% |
| EBT Per EBIT | 112.10% | 101.90% | 114.71% | 100.90% | 95.24% |
| Return on Assets (ROA) | -38.60% | -70.58% | -148.53% | -74.01% | -46.37% |
| Return on Equity (ROE) | -42.51% | -111.82% | -364.22% | -130.81% | -50.75% |
| Return on Capital Employed (ROCE) | -37.01% | -96.43% | -220.77% | -122.63% | -51.62% |
| Return on Invested Capital (ROIC) | -37.01% | -96.43% | -220.77% | -122.63% | -51.62% |
| Return on Tangible Assets | -38.60% | -70.58% | -148.53% | -74.01% | -46.43% |
| Earnings Yield | -13.21% | -11.15% | -30.27% | -12.35% | -7.20% |
| Efficiency Ratios | |||||
| Receivables Turnover | 7.81 | 7.59 | 3.23 | 9.22 | 2.18 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 12.73 | 9.67 | 10.65 | 10.97 | 7.62 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 3.50 |
| Asset Turnover | 0.34 | 0.65 | 0.70 | 0.75 | 0.10 |
| Working Capital Turnover Ratio | 0.55 | 1.21 | 0.96 | 0.81 | 0.09 |
| Cash Conversion Cycle | 75.43 | 85.85 | 147.41 | 72.85 | 215.05 |
| Days of Sales Outstanding | 46.74 | 48.11 | 113.13 | 39.59 | 167.16 |
| Days of Inventory Outstanding | 28.68 | 37.74 | 34.28 | 33.26 | 47.90 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 75.43 | 85.85 | 147.41 | 72.85 | 215.05 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -2.81 | -3.12 | -5.77 | -4.13 | -10.00 |
| Free Cash Flow Per Share | -3.00 | -3.12 | -5.78 | -4.15 | -10.25 |
| Dividend Paid and CapEx Coverage Ratio | -14.83 | -2921.22 | -467.45 | -147.39 | -40.14 |
| Capital Expenditure Coverage Ratio | -14.83 | -2921.22 | -467.45 | -147.39 | -40.14 |
| Operating Cash Flow Coverage Ratio | 0.00 | -15.96 | -11.49 | 0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | -1.14 | -1.09 | -2.01 | -0.70 | -5.30 |
| Free Cash Flow Yield | -14.29% | -11.15% | -28.92% | -8.84% | -8.33% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -7.58 | -8.97 | -3.30 | -8.09 | -13.89 |
| Price-to-Sales (P/S) Ratio | 8.53 | 9.75 | 6.98 | 7.98 | 65.23 |
| Price-to-Book (P/B) Ratio | 3.22 | 10.03 | 12.03 | 10.59 | 7.05 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -7.00 | -8.97 | -3.46 | -11.31 | -12.01 |
| Price-to-Operating Cash Flow Ratio | -7.47 | -8.97 | -3.47 | -11.39 | -12.30 |
| Price-to-Earnings Growth (PEG) Ratio | 0.68 | 0.19 | -0.80 | 0.14 | 0.39 |
| Enterprise Value Multiple | -5.93 | -8.04 | -2.98 | -7.27 | -11.82 |
| Enterprise Value | 4.80B | 6.53B | 3.83B | 7.94B | 18.79B |
| EV to EBITDA | -5.93 | -8.04 | -2.98 | -7.27 | -11.82 |
| EV to Sales | 5.94 | 8.71 | 6.29 | 6.99 | 56.51 |
| EV to Free Cash Flow | -4.88 | -8.01 | -3.12 | -9.92 | -10.40 |
| EV to Operating Cash Flow | -5.21 | -8.01 | -3.12 | -9.98 | -10.66 |
| Tangible Book Value Per Share | 6.53 | 2.79 | 1.66 | 4.44 | 17.42 |
| Shareholders’ Equity Per Share | 6.53 | 2.79 | 1.66 | 4.44 | 17.45 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Revenue Per Share | 2.46 | 2.87 | 2.87 | 5.89 | 1.89 |
| Net Income Per Share | -2.77 | -3.12 | -6.05 | -5.81 | -8.86 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.12 | 1.00 | 1.00 | 1.00 | 0.95 |
| Research & Development to Revenue | 0.66 | 0.65 | 1.11 | 0.63 | 4.14 |
| SG&A to Revenue | 0.36 | 0.39 | 0.43 | 0.38 | 0.85 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.01 | 0.03 | 0.00 |
| Income Quality | 1.01 | 1.00 | 0.95 | 0.71 | 1.13 |
Currency in JPY
